Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. - Wikidata - awgldk - TriplyDB

Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis.

Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis.

http://www.wikidata.org/entity/Q43248041

about

PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2 Pharmacogenomics of adverse drug reactions Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis Cytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohort The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1 Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol)Superoxide Dismutase Gene (SOD1, SOD2, and SOD3) Polymorphisms and Antituberculosis Drug-induced Hepatitis.Epidemiology and risk factors for drug allergy.Pharmacogenomics of antimicrobial agents.Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy.Clinical characteristics of drug-induced liver injury and related risk factors.Genetic association studies in drug-induced liver injury.Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity.Update meta-analysis of the CYP2E1 RsaI/PstI and DraI polymorphisms and risk of antituberculosis drug-induced hepatotoxicity: evidence from 26 studies.Drug metabolism and liver disease: a drug-gene-environment interaction.Pharmacogenomic strategies against microbial resistance: from bright to bleak to innovative.ABCC2 Haplotype is Associated With Antituberculosis Drug-Induced Maculopapular Eruption.PharmGKB summary: isoniazid pathway, pharmacokinetics.Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis.CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study.Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population.Safe and effective medicines for all: is personalized medicine the answer?Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.TNF-α genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis.NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption.N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group

P2860

Q27011622-C96B8DA4-5E42-4814-A206-059389F05CEF Q27015820-D7752151-545E-4773-A2CA-7D70B2EC79C2 Q28484468-A02F6A71-C6EE-4247-B77C-C7908D89F9BA Q28486869-1A961687-5510-42D4-964A-56DD49FD9AE2 Q28539060-F354D861-CE39-4A96-95D7-F042769CC9F1 Q33901424-0634556C-1EC3-4BD1-8F0E-8830A54C6D0A Q34760618-8EF2F075-1501-4BA3-B5FF-CDAF115FE96E Q34976470-0118E2C8-A75A-4460-82D7-0DC5B78C7ACC Q34977413-90BE10F5-E100-4821-9231-562FCC18BE8F Q35657599-38DF7073-0BE0-4481-9F58-0DB39243393B Q37289416-3C97D5DD-55E1-4A7C-9D16-5D95451D06B3 Q37931275-CA1B7661-A942-42EB-907F-C74F4F302FF4 Q38360770-7045403F-F37C-432A-82DF-DDDDABFBE4D3 Q38381479-92C6B151-92B4-480D-B667-152BC2DD5E9F Q39037269-BE2EFDEC-2D25-4075-88E4-0EEA0516F40B Q39835147-354EFA21-F42F-4416-85E8-B44243C8F095 Q42025168-3E571B06-0AD7-4947-8F48-D0358076A3B4 Q42090708-7B9E468E-74AB-493C-A5B3-55D2391B2FBB Q42335970-C824A31D-9242-43F8-86F9-74022741F8CA Q42696912-EBC7400F-043B-4DF8-AA8E-746BA643AD93 Q43474583-10B9872E-2DA7-43E5-9F7E-FEC170F91C28 Q43754598-5067B525-F7FC-481B-876A-EDE9DD18D6CB Q43885443-E219EC03-14E2-4F40-B98E-8BF12D899635 Q44483899-1AE79463-F54E-4292-BEF4-161EE579F00D Q51569750-9812D095-94F6-48E9-B827-8D03633479D0 Q53395242-174FCDFC-EFF5-4DA3-84C0-8A851548679D Q53455058-CD6EE722-EAA8-4A23-BD72-A63AFB837212 Q57302643-66E88996-F0B7-44BE-A69F-668BA2EC00DE

P2860

Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis.

http://www.wikidata.org/entity/Q43248041

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis.

@en

Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis.

@nl

type

label

Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis.

@en

Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis.

@nl

prefLabel

Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis.

@en

Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis.

@nl

P1433

Q43248041-F214DAF0-4D3A-4667-B6A3-40529A2CD53B

P1476

Q43248041-DE518B15-A3B4-48C4-87CE-040BB354EB9E

P2093

Q43248041-05F5393F-F540-4B71-8CC3-36CC39B0E41C

Q43248041-44CD7BC6-7582-41DA-A3FC-248E16FB38CA

Q43248041-4C45C985-F9AE-47D1-8B17-8A81311DE2B9

Q43248041-4FEEACB1-80B1-4E0D-9B41-77126A65EB64

Q43248041-65FFDBB1-0F11-474F-AFE2-FF10445DBFA6

Q43248041-8C86284E-964B-4D31-810B-5064C9384433

Q43248041-9EC02031-8F36-48D4-93C1-8AFCD466F3EC

Q43248041-A0C1993B-DEB4-4609-88A4-9474742601A7

Q43248041-B7191CDB-4357-427A-A3E2-E716B0FEA70A

Q43248041-B726774D-023B-49AF-B10C-31C83DFB9A09

P2860

Q43248041-0051F233-FB54-4B17-9CE1-FD7F7F71D5A3

Q43248041-1D1F8DAC-0E52-4761-8B15-068124249FCC

Q43248041-252A02E2-81E9-49C7-BF37-617B5FB4D44B

Q43248041-2D9368D4-9DED-4E81-B34A-56E8D0EB1A47

Q43248041-37D9E34D-199B-4116-9A1D-5F03AF9FB072

Q43248041-3C056A26-66F4-4968-9E56-36AB8679527F

Q43248041-51EF68C6-EBCE-4344-A5D4-88334859D818

Q43248041-59DEF05E-DCCB-4B0D-A690-08FD0CB014A7

Q43248041-5A892202-09E0-48EF-B3A9-A94F1A07D770

Q43248041-5DC89C49-DEC7-4939-B64F-8369B2CCFB7D

P304

Q43248041-97D50D49-759A-48AC-9266-360D0CECB3A4

P31

Q43248041-69151BB9-3008-4354-B6D2-21DEE7AEDE1D

P356

Q43248041-19D98DA0-CA0B-4F55-A5D4-47CC1C197541

P433

Q43248041-5A2E61A4-0D4D-4BD1-B306-E9193CFFB837

P478

Q43248041-4FEB2966-F887-4806-81B4-B1E3D31F75C5

P50

Q43248041-0C8A3F2B-4D24-4DFB-B7E7-B0538CEE864A

Q43248041-43FDA286-DBFA-4CC8-AE78-B6B2F4A10517

P577

Q43248041-7FD47B5E-DFE7-4091-A9FB-7D1E61259D82

P698

Q43248041-9D79833E-B9EA-4A84-BED0-7B8A49603E75

P356

P1433

Pharmacogenomics

P1476

Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis.

@en

P2093

Bo-Hyung Kim

http://www.w3.org/2001/XMLSchema#string

Eun-Soon Shin

http://www.w3.org/2001/XMLSchema#string

Hae-Sim Park

http://www.w3.org/2001/XMLSchema#string

In-Jin Jang

http://www.w3.org/2001/XMLSchema#string

Jae-Seuk Park

http://www.w3.org/2001/XMLSchema#string

Joon-Woo Bahn

http://www.w3.org/2001/XMLSchema#string

Junghan Song

http://www.w3.org/2001/XMLSchema#string

Kyung-Up Min

http://www.w3.org/2001/XMLSchema#string

Sang-Heon Kim

http://www.w3.org/2001/XMLSchema#string

Sang-Hoon Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

Drug-induced hepatotoxicity.

Criteria of drug-induced liver disorders. Report of an international consensus meeting.

An official ATS statement: hepatotoxicity of antituberculosis therapy.

NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.

Haplotype analysis in population genetics and association studies.

Gene SNPs and mutations in clinical genetic testing: haplotype-based testing and analysis.

Role of metabolism in drug-induced idiosyncratic hepatotoxicity.

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

P304

1767-1779

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.09.100

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Yoon-Seok Chang

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19891553

http://www.w3.org/2001/XMLSchema#string